Correspondence to editorials (CMH-2025-0699) on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”
1Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea 2Curome Biosciences Co., Ltd, Seoul, Korea 3Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Corresponding author:
Do Hyun Park, Tel: +82-2-3010-3194, Fax: +82-2-476-0824, Email: dhpark@amc.seoul.kr
